Do you want to read an article? Please log in or register.
SAKK 16/14: Adding durvalumab to neoadjuvant chemotherapy achieves encouraging EFS and OS in patients with resectable stage IIIA(N2) NSCLC
Lung, Respiratory and Thoracic Cancer
ELCC 2025
Related content
SPECIAL REPORT
Lung, Respiratory and Thoracic Cancer
Neoadjuvant Nivolumab plus chemotherapy in resectable NSCLC
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
★ 2
Recommended by
Dr Wolf-Dieter Janthur, Faculty Member
Lancet
Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Arunachalam A, Keller SM, Samkari A, Gao S, KEYNOTE-671 Investigators
doi: 10.1016/S0140-6736(24)01756-2
ESMO 2024
Lung, Respiratory and Thoracic Cancer
MARIPOSA-2: OS data continued to favor amivantamab plus chemotherapy over chemotherapy alone in patients with EGFR-mutated NSCLC
Lung, Respiratory and Thoracic Cancer
Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis
J Thorac Oncol
Marinelli D, Nuccio A, Di Federico A, Ambrosi F, Bertoglio P, Faccioli E, Ferrara R, Ferro A, Giusti R, Guerrera F, Mammana M, Pittaro A, Sepulcri M, Viscardi G, Gallina FT
doi: 10.1016/j.jtho.2024.09.1443
ELCC 2025
Lung, Respiratory and Thoracic Cancer
LAURA: Improved trend for OS benefit with osimertinib versus placebo in patients with unresectable stage III EGFR-mutant NSCLC
Lung, Respiratory and Thoracic Cancer
Prevalence of EGFR Mutations in Patients With Resected Stage I-III NSCLC: Results From the EARLY-EGFR Study
J Thorac Oncol
Soo RA, Reungwetwattana T, Perroud HA, Batra U, Kilickap S, Tejado Gallegos LF, Donner N, Elsayed M, Huggenberger R, Van Tu D
doi: 10.1016/j.jtho.2024.06.008
Lung, Respiratory and Thoracic Cancer
Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R
ESMO Open
Filippi AR, Bar J, Chouaid C, Christoph DC, Field JK, Fietkau R, Garassino MC, Garrido P, Haakensen VD, Kao S, Markman B, McDonald F, Mornex F, Moskovitz M, Peters S, Sibille A, Siva S, van den Heuvel M, Vercauter P, Anand S, Chander P, Licour M, de Lima AR, Qiao Y, Girard N
doi: 10.1016/j.esmoop.2024.103464
ASCO 2024
Lung, Respiratory and Thoracic Cancer
Practice-changing results with osimertinib (LAURA) and durvalumab (ADRIATIC) in patients with lung cancer
Lung, Respiratory and Thoracic Cancer
Neoadjuvant and Adjuvant Treatment for Early-Stage Resectable Non-small Cell Lung Cancer (NSCLC): Consensus Recommendations from the International Association for the Study of Lung Cancer (IASLC)
J Thorac Oncol
Spicer JD, Cascone T, Wynes MW, Ahn MJ, Dacic S, Felip E, Forde PM, Higgins KA, Kris MG, Mitsudomi T, Provencio M, Senan S, Solomon BJ, Tsao MS, Tsuboi M, Wakelee HA, Wu YL, Chih-Hsin Yang J, Zhou C, Harpole DH, Kelly KL
doi: 10.1016/j.jtho.2024.06.010